I hear that!  One of the ways that CTIX's pipeline sticks out is that at least two of their drugs, one of which is in phase 2, have a much broader application than their peers.  When approvals start to happen, there will be an avalanche of indications that now have a new and better treatment.  Plenty of bio startups out there have a drug going through trials for very specific subsets of subsets of diseases, well not CTIX - all of Cellceutix's current trial drugs have some major game-changing potential.  Yeah - we'll probably also cover our peers' indications. Ouch.